

Glenmark launches Sitagliptin for adults with Type 2 diabetes in India

07 July 2022 | News

The company has introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT



Glenmark Pharmaceuticals has launched sitagliptin and its Fixed Dose Combinations (FDCs), at an affordable price for adults with Type 2 diabetes in India. The company has introduced eight different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price.

The medicines will be available under the brand name SITAZIT, SITAZIT- M, SITAZIT- M ER and SITAZIT D.

Each of these brands will have two different variants – SITAZIT (sitagliptin) will be available in 50 mg and 100 mg variants; SITAZIT M will have sitagliptin (50 mg) + metformin (500 mg/ 1000 mg); SITAZIT M ER will have sitagliptin (100 mg) + metformin SR (500 mg/ 1000 mg). The brand SITAZIT D is a new combination with two variants SITAZIT D 100/10, which will have sitagliptin (100 mg) + dapagliflozin (10 mg) and SITAZIT D 50/5 which will have sitagliptin (50 mg) + dapagliflozin (5 mg).